HOME   |    PDF   |   


Podocalyxin in the onset of nephropathy among Indian type 2 diabetes mellitus patients



Balaji Viswanatha Setty1, Gutlur Nagarajaiah Setty Raghav2*, Hareesh Rangaswamaiah3 & Veluri Ganesh4



1Department of General Medicine, Rajarajeshwari Medical College and Hospital, Bangalore, Karnataka, India; 2Department of General Medicine, Rajarajeshwari Medical College and Hospital, Bangalore, Karnataka , India; 3Department of General Medicine, Akash Institute of Medical Sciences and Research Centre, Bangalore, Karnataka, India; 4Department of Biochemistry, ESIC Medical College and Hospital, Kalaburagi, Karnataka, India.



Balaji Viswanatha Setty - Email: baluthedoc1@gmail.com

Gutlur Nagarajaiah Setty Raghav - Email: rgutlur@gmail.com

Dr. Hareesh Rangaswamaiah - Email: hareesh22578@gmail.com

Veluri Ganesh - Email: ganeshbabu370@gmail.com


Article Type

Research Article



Received December 1, 2023; Revised December 31, 2023; Accepted December 31, 2023, Published December 31, 2023



The diabetic nephropathy is one of the most prevalent microvascular complications with type 2 diabetes mellitus. The most accurate and widely used marker for diabetic nephropathy is microalbuminuria and it is also regarded as conventional method. However, it is not a sensitive or specific nephropathy biomarker. Therefore, it is of interest to evaluate the role of podocalyxin to predict early onset of nephropathy in patients with type 2 diabetes mellitus. This cross sectional study is conducted on 150 subjects. Among these 150 T2DM patients (Group 2: T2DM with normoalbuminuria and Group 3: T2DM with microalbuminuria) and 50 were age, gender and BMI matched healthy controls (Group 1). The biochemical and experimental parameters was analyzed. T2DM patients have higher levels of urine podocalyxin. This level was significantly elevated in patients with T2DM with microalbuminuria than normoalbuminuria. Urinary podocalyxin levels and HbA1c were found to be positively correlated. Thus, urinary podocalyxin is useful as early predictable marker for nephropathy in patients with type 2 diabetes mellitus.



Type 2 diabetes mellitus, nephropathy, microalbumin and podocalyxin



Setty et al. Bioinformation 19(12): 1124-1128 (2023)


Edited by

P Kangueane






Biomedical Informatics



This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.